Daewon Pharm (003220) - Total Assets
Based on the latest financial reports, Daewon Pharm (003220) holds total assets worth ₩613.65 Billion KRW (≈ $415.86 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 003220 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Daewon Pharm - Total Assets Trend (2011–2025)
This chart illustrates how Daewon Pharm's total assets have evolved over time, based on quarterly financial data. Explore Daewon Pharm strategic investment ratio to see how much of total assets are deployed in long-term investments.
Daewon Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Daewon Pharm's total assets of ₩613.65 Billion consist of 41.8% current assets and 58.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.7% |
| Accounts Receivable | ₩77.12 Billion | 12.6% |
| Inventory | ₩97.83 Billion | 15.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩56.48 Billion | 9.2% |
| Goodwill | ₩6.00 Billion | 1.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Daewon Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Daewon Pharm (003220) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daewon Pharm's current assets represent 41.8% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2025, down from 12.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 15.9% of total assets.
Daewon Pharm Competitors by Total Assets
Key competitors of Daewon Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Bausch Health Companies Inc
TO:BHC
|
Canada | CA$24.50 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.80 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Hainan Haiyao Co Ltd
SHE:000566
|
China | CN¥5.79 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥4.51 Billion |
Daewon Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.28 | 1.72 |
| Quick Ratio | 0.73 | 0.72 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩40.27 Billion | ₩56.79 Billion | ₩54.71 Billion |
Daewon Pharm - Advanced Valuation Insights
This section examines the relationship between Daewon Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.82 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | ₩613.65 Billion |
| Market Capitalization | $124.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daewon Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Daewon Pharm's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Daewon Pharm (2011–2025)
The table below shows the annual total assets of Daewon Pharm from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩613.65 Billion ≈ $415.86 Million |
+5.19% |
| 2024-12-31 | ₩583.39 Billion ≈ $395.35 Million |
+14.84% |
| 2023-12-31 | ₩508.00 Billion ≈ $344.26 Million |
+12.00% |
| 2022-12-31 | ₩453.55 Billion ≈ $307.36 Million |
+5.58% |
| 2021-12-31 | ₩429.58 Billion ≈ $291.12 Million |
+28.15% |
| 2020-12-31 | ₩335.21 Billion ≈ $227.17 Million |
+2.35% |
| 2019-12-31 | ₩327.53 Billion ≈ $221.96 Million |
+18.91% |
| 2018-12-31 | ₩275.44 Billion ≈ $186.66 Million |
+21.23% |
| 2017-12-31 | ₩227.20 Billion ≈ $153.97 Million |
+5.83% |
| 2016-12-31 | ₩214.68 Billion ≈ $145.49 Million |
+10.23% |
| 2015-12-31 | ₩194.75 Billion ≈ $131.98 Million |
+7.82% |
| 2014-12-31 | ₩180.62 Billion ≈ $122.40 Million |
+12.79% |
| 2013-12-31 | ₩160.14 Billion ≈ $108.52 Million |
+8.85% |
| 2012-12-31 | ₩147.13 Billion ≈ $99.70 Million |
+4.80% |
| 2011-12-31 | ₩140.39 Billion ≈ $95.14 Million |
-- |
About Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more